Evidence map›Paper›PMID 38015820›Full record

ArticleJournal of proteome research2024

Multicenter Collaborative Study to Optimize Mass Spectrometry Workflows of Clinical Specimens.

Oliver Kardell, Christine von Toerne, Juliane Merl-Pham, Ann-Christine König, Marcel Blindert, Teresa K Barth, Julia Mergner, Christina Ludwig, Johanna Tüshaus, Stephan Eckert and 13 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of proteome research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Oliver KardellMetabolomics and Proteomics Core (MPC), Helmholtz Zentrum München,German Research Center for Environmental Health (GmbH), Munich 80939, Germany.ORCID 0000-0002-6703-7997
Christine von ToerneMetabolomics and Proteomics Core (MPC), Helmholtz Zentrum München,German Research Center for Environmental Health (GmbH), Munich 80939, Germany.
Juliane Merl-PhamMetabolomics and Proteomics Core (MPC), Helmholtz Zentrum München,German Research Center for Environmental Health (GmbH), Munich 80939, Germany.
Ann-Christine KönigMetabolomics and Proteomics Core (MPC), Helmholtz Zentrum München,German Research Center for Environmental Health (GmbH), Munich 80939, Germany.
Marcel BlindertMetabolomics and Proteomics Core (MPC), Helmholtz Zentrum München,German Research Center for Environmental Health (GmbH), Munich 80939, Germany.
Teresa K BarthClinical Protein Analysis Unit (ClinZfP), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-University (LMU) Munich, Großhaderner Straße 9, Martinsried 82152, Germany.
Julia MergnerBavarian Center for Biomolecular Mass Spectrometry at Klinikum Rechts der Isar (BayBioMS@MRI), Technical University of Munich, Munich 80333, Germany.
Christina LudwigBavarian Center for Biomolecular Mass Spectrometry (BayBioMS), TUM School of Life Sciences, Technical University of Munich, Freising 85354, Germany.ORCID 0000-0002-6131-7322
Johanna TüshausChair of Proteomics and Bioanalytics, Technical University of Munich, Freising 85354, Germany.
Stephan EckertChair of Proteomics and Bioanalytics, Technical University of Munich, Freising 85354, Germany.
Stephan A MüllerGerman Center for Neurodegenerative Diseases (DZNE) Munich, DZNE, Munich 81377, Germany.
Stephan BreimannGerman Center for Neurodegenerative Diseases (DZNE) Munich, DZNE, Munich 81377, Germany.ORCID 0000-0002-0305-3373
Pieter GiesbertzGerman Center for Neurodegenerative Diseases (DZNE) Munich, DZNE, Munich 81377, Germany.
Alexander M BernhardtGerman Center for Neurodegenerative Diseases (DZNE) Munich, DZNE, Munich 81377, Germany.ORCID 0000-0002-2572-5062
Lisa SchweizerDepartment of Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Martinsried 82152, Germany.
Vincent AlbrechtDepartment of Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Martinsried 82152, Germany.
Daniel TeupserInstitute of Laboratory Medicine, University Hospital, LMU Munich, Munich 81377, Germany.
Axel ImhofClinical Protein Analysis Unit (ClinZfP), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-University (LMU) Munich, Großhaderner Straße 9, Martinsried 82152, Germany.ORCID 0000-0003-2993-8249
Bernhard KusterBavarian Center for Biomolecular Mass Spectrometry (BayBioMS), TUM School of Life Sciences, Technical University of Munich, Freising 85354, Germany.ORCID 0000-0002-9094-1677
Stefan F LichtenthalerGerman Center for Neurodegenerative Diseases (DZNE) Munich, DZNE, Munich 81377, Germany.
Matthias MannDepartment of Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Martinsried 82152, Germany.
Jürgen CoxComputational Systems Biochemistry Research Group, Max-Planck Institute of Biochemistry, Martinsried 82152, Germany.ORCID 0000-0001-8597-205X
Stefanie M HauckMetabolomics and Proteomics Core (MPC), Helmholtz Zentrum München,German Research Center for Environmental Health (GmbH), Munich 80939, Germany.ORCID 0000-0002-1630-6827

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The foundation for integrating mass spectrometry (MS)-based proteomics into systems medicine is the development of standardized start-to-finish and fit-for-purpose workflows for clinical specimens. An essential step in this pursuit is to highlight the common ground in a diverse landscape of different sample preparation techniques and liquid chromatography-mass spectrometry (LC-MS) setups. With the aim to benchmark and improve the current best practices among the proteomics MS laboratories of the CLINSPECT-M consortium, we performed two consecutive round-robin studies with full freedom to operate in terms of sample preparation and MS measurements. The six study partners were provided with two clinically relevant sample matrices: plasma and cerebrospinal fluid (CSF). In the first round, each laboratory applied their current best practice protocol for the respective matrix. Based on the achieved results and following a transparent exchange of all lab-specific protocols within the consortium, each laboratory could advance their methods before measuring the same samples in the second acquisition round. Both time points are compared with respect to identifications (IDs), data completeness, and precision, as well as reproducibility. As a result, the individual performances of participating study centers were improved in the second measurement, emphasizing the effect and importance of the expert-driven exchange of best practices for direct practical improvements.

Indexed as

PlasmaTandem Mass SpectrometryChromatography, LiquidReproducibility of ResultsWorkflowclinical specimenCSFdata-dependent acquisitiondata-independent acquisitioninterlaboratoryintralaboratoryLC–MSmass spectrometryplasmaround-robin studyR package mpwR

Identifiers

PMID38015820
PMCPMC10775142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.